Stocktoria
BECTON DICKINSON & CO BDX
BECTON DICKINSON & CO (BDX) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 2.78% (safety: stretched). FY2025 revenue was $21.8B at a 7.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.81 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-07 | Citigroup | Buy (main) |
| 2026-08-07 | RBC Capital | Sector Perform (main) |
| 2026-08-07 | Piper Sandler | Neutral (main) |
| 2026-08-07 | Wells Fargo | Equal-Weight (main) |
| 2026-08-05 | TD Cowen | Hold (main) |
| 2026-07-28 | UBS | Buy (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.017 |
| Retained earnings / assets | 0.3 |
| EBIT / assets | 0.047 |
| Equity / liabilities | 0.848 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BDX | BECTON DICKINSON & CO | 6/9 | 2.29 | 25.6 | +8.2% |
| BSX | BOSTON SCIENTIFIC CORP | 4/9 | 2.81 | — | +19.9% |
| MMM | 3M CO | 5/9 | 5.46 | 26.3 | +1.5% |
| SYK | STRYKER CORP | 4/9 | 3.96 | 39.3 | +11.2% |
| MDLN | Medline Inc. | 6/9 | 2.84 | 44.1 | +11.5% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
| SOLV | Solventum Corp | 6/9 | 2.34 | 8.9 | +0.9% |
About BECTON DICKINSON & CO
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
FAQ
Is BDX financially healthy?
BECTON DICKINSON & CO's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does BDX pay a dividend, and is it safe?
Yes. BECTON DICKINSON & CO pays a dividend yielding about 2.78% with a 71.3% payout ratio, rated “stretched” for safety.
How profitable is BDX?
In FY2025, BECTON DICKINSON & CO had a net margin of 7.7% and a return on equity of 6.6%.
Is BDX overvalued or undervalued?
BECTON DICKINSON & CO trades at about 31.5× trailing earnings — near its 10-year norm (10-year range 24.1×–294.7×, median 34.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for BDX?
The average Wall-Street price target for BECTON DICKINSON & CO is $192.00, about 4.6% above the recent price, from 12 analysts (consensus: buy).
Is BDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BECTON DICKINSON & CO: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 25.6×, a dividend yield of 2.78%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.